Medezin: one product from Australia and the trap of two names

Who is Medezin and where does its dried flower come from?

Medezin is a pharmaceutical company based in Łódź, which is responsible for one product with hemp flower in the Polish market. It does not cultivate the plants: the raw material comes from Australia, from the company Little Green Pharma, and Medezin is listed as the responsible entity, meaning the party importing the goods into the country and responsible for its distribution.

The company's own website describes it without a single word about hemp. It mentions the import and certification of medicines, distribution, storage, and repackaging, provides an address in Łódź and a facility in Konstantynów Łódzki. Hemp flower is just one of many things that can be imported and distributed, not a separate line item described in the offer.

Behind the company is Pelion, the largest healthcare operator in Poland and Lithuania, owner of a pharmaceutical wholesaler and a chain of pharmacies. Industry reports indicate the year 2023 as the time the raw material was entered into circulation, and the first packages reached pharmacies in March 2024. Sources do not even agree on the legal form: the pharmacy database and the company's own website refer to a limited liability company, while the market review mentions a joint-stock company.

In this arrangement of roles, the manufacturer and the responsible entity are not the same. The Australian company conducts cultivation and prepares the raw material, while the Polish company takes on the task of introducing it into circulation and contacting authorities. The name on the pharmacy package belongs to the latter, so the patient reads the name of the importer, not the name of the plantation. Therefore, in our list, this product is listed under Medezin, even though no shrub has grown in Poland.

Which varieties of Medezin reach Polish pharmacies?

One. In our list of one hundred forty-one pharmacy items, Medezin has exactly one entry, Desert Flame, and the same is indicated in the profile database. Two other suppliers have such a narrow offer, while the largest of the sixteen manufacturers is responsible for thirty-eight varieties.

The declared THC content is in the range of 18.0-22.0%. The profile source provides one nominal value and allows for a deviation of ten percent in either direction, hence the range instead of a single number: between batches of the same product, the analysis does not come out identically twice. The CBD content is declared as less than one percent.

One item from the supplier means something different for the patient than one item in the catalog. With thirty-eight labels from one manufacturer, a supply interruption can usually be circumvented by another label from the same company. Here, there is no such reserve: when this item disappears from circulation, the entire market share of this supplier in dried flower disappears with it, and the person who selected therapy based on it returns to choosing between manufacturers.

The leading terpene of this item does not distinguish it from the list. Myrcene is at the forefront of the profile in twenty of the eighty-five varieties we have collected, so in this respect, Desert Flame belongs to the largest family in Polish pharmacies. Separately, the number of packages stands out: it is one of fifty-eight varieties for which there is exactly one pharmacy item in the entire list.

How does the raw material of Medezin differ from the raw material of other suppliers?

By process rather than by plant. Medezin does not conduct cultivation or extraction: it imports ready-made dried flower from an Australian plantation, certifies it, and introduces it into circulation. The difference compared to suppliers with their own cultivation lies in the supply chain and the commercial agreement, not in the technology of producing the raw material itself.

The pharmacy record indicates only this: floral form, fifteen-gram packaging, designation of a narcotic substance, and a note about dispensing by prescription. The rest of what circulates about this company comes from the stock market announcement of the Australian partner. It describes a five-year agreement for the distribution of oils and dried flower and exclusivity dependent on sales thresholds: one-fifth of the oil market and one-tenth of the high-potency dried flower market.

The commercial declaration is not a quality document. The distribution agreement speaks of ambitions for market share, not about how a specific batch grew and how it was dried. Neither the pharmacy database nor the company's website publish a certificate of analysis for the batch, so comparing this raw material with that of another supplier can only be done at the label level today.

One point from the same announcement, however, directly concerns quality. The parties announced the signing of a technical agreement under good manufacturing practice before the first shipment, meaning the requirements for the product were established by contract between the companies. No one has published the contents of this contract, so the reader only knows that the document exists. This is where the boundary lies, where fact ends and assurance begins.

What is known, and what is not known about the raw material of this supplier?

It is known what is on the packaging, and almost nothing beyond that. The pharmacy database provides the responsible entity, floral form, as well as weight and declared potency. There is no public certificate of analysis, no name of the laboratory, nor clinical study conducted on the raw material of this company, and market reports speak of one delivery.

The terpene profile of this product is described by one Polish strain database and no one else. It lists five components with myrcene at the forefront, alongside caryophyllene, limonene, humulene, and pinene. Leading terpene collects strains with a similar profile on a separate page. We do not transcribe percentage shares from here, as it is unclear what they are calculated for.

This is evident from the numbers themselves. The five values provided for this item sum up to 78 percent, and the same five in the clinical description stand next to a sixth column simply named 'others', which completes the hundred. In the same database, one hundred and forty-five items yield forty-six different sums, ranging from fourteen to one hundred and twenty-five, with a median of eighty-two. A number that sometimes represents a part of the whole and sometimes a part of a known part is not a measurement.

The third group consists of reviews. A public patient review describes the appearance and smell of this batch and directly indicates the Australian origin of the dried flower, but does not refer to any laboratory document. Such a text is a testament to one person's experience, and we treat it as such here.

What adverse effects have been reported after using the Medezin raw material?

None separately. There is no public compilation of reports attributed to this manufacturer or this single item, and with one delivery to pharmacies, the number of people who used it is too small for any registry to derive anything from it. The following therefore pertains to the entire group of raw materials.

Reports of adverse effects are collected for medicinal products with a batch number, not for the strain name, so the following pertains to hemp dried flower as a group of raw materials. The most frequently reported symptoms are dry mouth, red eyes, and increased heart rate. Dizziness upon rapid standing, daytime drowsiness, and temporary worsening of short-term memory are less frequently described, as well as anxiety that increases with dosage. A separate issue is medications taken concurrently, especially sedatives and those affecting coagulation: their assessment requires knowledge of the entire list of preparations, not just the description of the plant. We do not provide the frequency of these symptoms numerically, as public compilations for hemp dried flower in Poland do not separate them by individual products.

This item also includes the method of administration. The dried flower reaches the pharmacy in floral form, so it may be vaporized or brewed as an infusion, which shifts both the threshold for the appearance of symptoms and their duration. The choice of method of administration and portion size is up to the attending physician, not the strain description.

Why is the composition of this item so easily lost in strain databases?

Because the same item has three different names, and none of them is complete. The pharmacy list records it as Desert Flame, the profile database titled it Amnesia Haze with Desert Flame in parentheses, and the registered name does not include the strain name at all, as it only mentions the manufacturer and potency.

Amnesia Haze does not appear in the Polish list as a separate strain, yet it holds the top position in the title of the profile page and in its address. Our stream indexed source items by the base name extracted from the address, so the record with the full composition fell under a term that does not exist in the inventory and quietly dropped out of agreement. Until August 30, 2026, the page about this strain claimed that the composition could not be determined, even though a file with five names lay in the same repository.

The fix is easy to describe and unpleasant to find: when the title of the item names the inventory entry more accurately than the base name, the title prevails. Verified across all one hundred and forty-six items in both profile databases, the rule precisely indexed four records and did not affect any others. A practical conclusion for anyone searching for data about dried flower by trade name: also check under the alternative name in parentheses and the registered name, as the strain database search engine will show a void where data exists, just under a different term.

Is the only item from Medezin currently available at the pharmacy?

Checked on August 30, 2026: the profile database shows this item as unavailable. An entry in the list and presence on the shelf are two different things, and industry reports speak of a single delivery after which the product disappeared. Availability changes faster than any strain description.

There are several reasons, and none pertain to the quality of the dried flower itself. The permit for the trade of pharmaceutical raw material is valid for years, and one delivery is sufficient for several months of sales. The importer orders another batch when they see demand and when the partner on the other side of the world can cover it, and between one and the other, a year can pass. The distance adds to this: the batch comes from Australia, so the usual order cycle must account for transport and customs clearance, and delays on that side are reflected on the Polish shelf with several months of lag.

That is why we keep the current state in one place, not in strain descriptions: a list of currently available medical marijuana strains is refreshed along with the list and only there does it make sense to check what is currently available in the pharmacy. The profile itself, lineage, and what is unknown about this strain are described separately in the strain text. Desert Flame. A completely different group of goods is the store category dried flower from industrial hemp, available without a prescription and not a substitute for pharmaceutical raw material.

Frequently asked questions about dried flower from Medezin

How many strains does Medezin supply to Polish pharmacies?

One. In the list of one hundred and forty-one pharmacy items, the company has one entry, Desert Flame, and no other strain is assigned to it.

Where does the dried flower sold under the name Desert Flame come from?

From Australia, from the cultivation of Little Green Pharma. Medezin imports it to Poland as the responsible entity and does not conduct its own cultivation.

Why does the same item appear under two names?

The profile database records it as Amnesia Haze with the note Desert Flame in parentheses, while the Polish pharmacy list uses only the name Desert Flame. The registered name does not include either.

Does Medezin publish a certificate of analysis for its dried flower?

We did not find such a document either on the company's website or in pharmacy databases. Only label data is publicly available.

What THC content is declared for this item?

The range is 18.0-22.0%, which is a nominal value with an allowable deviation of ten percent in either direction. We do not provide a single number, as it does not reflect the variability between batches.

Can the dried flower from Medezin be purchased without a prescription?

No. Dried hemp is a pharmaceutical raw material issued by a doctor's prescription in the Rpw category, so it is not available outside of pharmacies and without a prescription.

Can this strain be bought in a pharmacy today?

The profile database shows availability described as none, checked on August 30, 2026. We gather the current status in the cluster hub, as it changes faster than strain descriptions.

Dried hemp is a pharmaceutical raw material issued by a doctor's prescription in the Rpw category. The material is informational in nature, describes the state of evidence, and does not replace consultation with the attending physician. Editorial text: Redakcja ubucha.pl.